Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
Search results
521 results
-
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Psoriasis - briakinumab (suspended) [ID65]
In development [GID-TAG412] Expected publication date: TBC
-
Osteoarthritis - naproxcinod [ID417]
In development [GID-TAG426] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]
In development [GID-TAG456] Expected publication date: TBC
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
In development [GID-TAG399] Expected publication date: TBC
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
In development [GID-TAG398] Expected publication date: 01 January 2011
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
In development [GID-TAG414] Expected publication date: TBC
-
Diabetic foot ulcers - new treatments [ID381]
In development [GID-TAG371] Expected publication date: TBC
-
Venous leg ulcers - new treatments [ID394]
In development [GID-TAG370] Expected publication date: TBC
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
In development [GID-TAG378] Expected publication date: TBC
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-TA10690] Expected publication date: TBC
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
In development [GID-TAG363] Expected publication date: TBC
-
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
In development [GID-TAG425] Expected publication date: TBC
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
In development [GID-TAG382] Expected publication date: TBC
-
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
In development [GID-TA10667] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
In development [GID-TA10701] Expected publication date: 20 July 2022
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 04 May 2022
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
In development [GID-TAG300] Expected publication date: TBC
-
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
In development [GID-TAG440] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC
-
Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Heart failure (acute decompensated) - nesiritide [ID384]
In development [GID-TAG376] Expected publication date: TBC